New York, Jan 12, 2026, 14:15 EST — Regular session
- Shares tick higher in afternoon trading after Goldman Sachs kicks off coverage with a Buy rating and $330 price target
- Goldman highlights “AI adoption” as a key demand driver; investors await clearer signs of Agentforce revenue growth
- Salesforce will present at the J.P. Morgan Healthcare Conference on Jan. 13
Salesforce shares nudged higher Monday after Goldman Sachs analyst Gabriela Borges initiated coverage with a Buy rating and set a $330 price target. Borges highlighted AI adoption as a “positive tailwind” for software demand. The stock climbed 0.3% to $260.76 in mid-afternoon trading in New York. TipRanks
The call comes as investors seek solid proof that Salesforce can convert Agentforce—its AI-driven task automation initiative—into accelerated subscription growth, rather than just generating demos and pilots.
A major Wall Street bank’s fresh coverage can move a stock like Salesforce, given the crowded positioning where even slight shifts in sentiment can trigger flows. This update comes just before the company’s appearance at a key investor conference this week.
Goldman, in a note flagged by Investing.com, estimates Agentforce could boost Salesforce’s “Platform and Other” revenue by about 4% over the next 12 to 18 months, potentially sparking a revenue inflection as soon as 2026. However, the bank also warns that gains might be partly offset by continued share declines in Commerce and Marketing Cloud. Investing.com
The broader market held steady as the S&P 500-linked SPY ETF gained roughly 0.2%, with the tech-focused QQQ matching that rise. ServiceNow edged up 0.8%, while Oracle jumped 3.3%.
Salesforce is pushing growth by doubling down on AI and data tools. In its December quarter, the company boosted its full-year revenue forecast to between $41.45 billion and $41.55 billion. Meanwhile, Agentforce and Data 360 annual recurring revenue — a key subscription metric — hit nearly $1.4 billion, soaring 114% from the previous year.
The next key event is Tuesday, when Salesforce President of Sales Mark Sullivan will speak at the J.P. Morgan Healthcare Conference at 2:15 p.m. PT, per the company’s events calendar.
Salesforce hasn’t set a date for its upcoming earnings release yet, though Nasdaq’s earnings calendar pegs it around Feb. 25. That report usually offers a key look at whether new products are beginning to boost billings and guidance.
The AI trade can shift fast. If customers drag their feet moving from trials to full rollouts — or if competitors snag deals through better pricing or integration — revenue growth might fall short, despite optimistic research notes.
Monday’s shift was modest. Attention now turns to Tuesday’s conference remarks for signals on demand in a crucial industry segment, followed by the upcoming earnings report later this quarter to gauge 2026 momentum more clearly.
Related articles: NYSE:CRM
